Clinical Trials

    Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    Investigator: Jun Zhang

    Study Coordinator: Fernanda Crutchfield

    Status: Enrolling

    ClinicalTrials.gov Number: NCT06616584

    Phone: 713.534.2773

    Protocol Number: PRO00046557

    Description


    This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody that stimulates the immune system by blocking the PD-1 pathway.